Sino-American Pharmaceutical Professionals Association ...

Virtual Session

June 25-26, 2021

2021 SAPA Healthcare Investment Forum &

Roadshow

Sino-American

Pharmaceutical

Professionals

Association

Title Sponsor

2 Table of Content

3 Title Sponsor

4 2021 SAPA Healthcare Investment Forum &

Roadshow: Vision and Mission, Introductions

7 Organizing Committee

8 Event Schedule & Agenda

11 Project List

13 Project Highlights from the Past Events*

14 Speakers, Panelists, Investors, and

Roadshow Judges

27 Roadshow Judges

29 Session Leaders & Moderators

31 Investors, Corporate BD, and Tech Transfer

Offices

32 Event Sponsors & Strategic Partners

33 SAPA Corporate Sponsors

37 Save the Date: Upcoming SAPA Events

40 SAPA Introduction and Contact Information

* From the previous SAPA Healthcare Investment Forums and Roadshows

4 2021 SAPA Healthcare

Investment Forum &

Roadshow

• Vision:To become the premium platform

for investors and entrepreneurs in

healthcare.

• Mission: To connect with trusted partners

and offer effective solutions and

support to emerging enterprises in

healthcare.

5

Aiming to meet the needs of healthcare advancement and

bridge break-through science and capital investment, SAPA is

planning to host its 4th annual Healthcare Investment Forum

and Roadshow to focus on the latest trends and

development in the area of healthcare investment. This

year’s event will still be held virtually to continue our efforts on

this premium flagship event on Friday, June 25 and Saturday,

June 26, 2021.

• Promote business cooperation in healthcare and

pharmaceutical industry

• Learn the up-to-date trend and outlook of life-science

investment

• Discuss and learn how to attract and engage angel

investors

• Host roadshow programs where the brightest ideas meet

the capital investors

• Utilize 1:1 session meetings and in-depth discussions

between the entrepreneur executives and investors

• Join the networking sessions to create more opportunities

We are looking forward to your participation to make it

another successful event.

2021 SAPA Healthcare

Investment Forum &

Roadshow

6Investment is crucial for companies in life sciences to survive,

prosper and bring your innovations to the next stage,

especially in this challenging era of COVID-19 Pandemic.

Get more funding and stay on the safe side!

Come and join the 2021 SAPA Healthcare Investment Forum

and Roadshow!

• Learn the newest trend of investment and development

• Interact with the top investors in life sciences

• Access to a full spectrum of investors from angel fund to

late stage investors, as well as BD representatives from

biotech and pharma

• 1:1 deep-dive meetings providing opportunities to

showcase your project

• Opportunities to out-license your technology and product

• Receive professional review and suggestions for your

roadshow materials, and get endorsed by the

pharmaceutical veterans at SAPA

• Connect with your peers, share your experience and

learning in securing the investments

• Establish connections and open your door to talents,

partners and many other resources

• Virtual format with easy remote access and review the

forum materials post-meeting

Why Participate

7 Organizing Committee

of 2021 SAPA Healthcare

Investment Forum & Roadshow

Xiaodong Chen

Stephen Xue

Bob Ai

Bob Ai

Yunqi An

Cythia Cai

Jiangchao Chen

Xiaodong Chen

Gang Cheng

Haipeng Cheng

Yvonne Cheng

Wei Deng

Chenchao Gao

Iris Gao

Andy Han

Committee Members

Event Chair and Co-Chairs

May Huang

Brian Jiang

Zosia Jiang

Xue Liang

Jerry Liu

Jiajun Mei

Pan Pan

Ginny Peng

Eric Rong

John Sun

Mark Tang

Michelle Tao

Support Team

WeChat

Lan Deng

Yuantao Li

Dengpan Liang

Xiaonan Liu

Jinqi Zhan

Zoom

Yicong Le

Yao Liu

Muyun Xu

Taoyu Zhu

Hui Wang

Xiaowen Wang

Hongye Wei

Jack Wu

Aiguo Xu

Stephen Xue

Xiaojiao Xue

Yan Yan

Aming Zhang

Yulan Zhang

Yiming Zhao

Ye Zhou

8 Event Schedule

Wednesday May 26

Business Pitch Bootcamp

8:30 pm – 10:00 pm How to successfully pitch your business ideas

to investors

Saturday June 5

Pre-Roadshow Session I

Saturday June 12

Pre-Roadshow Session II

Friday June 25

Roadshow Session

Saturday June 26

Morning Session

Afternoon Session

Friday June 25 – Tuesday June 29

Pre-scheduled Private 1:1 Meetings

9:00 pm – 11:00 pm SAPA investment pre-Roadshow I

9:00 pm – 11:00 pm SAPA investment pre-Roadshow II

8:00 pm – 11:00 pm SAPA investment final roadshow

All dates and times are in US Eastern Daylight Time (UTC-4).

Title Sponsor

9 Agenda

Friday June 25

Roadshow Session

8:00 pm – 11:00 pm SAPA Investment Final Roadshow

8:00 pm – 8:10 pm Opening Remarks

8:10 pm – 8:25 pm Accufusion Therapeutics

8:25 pm – 8:40 pm Acon Pharmaceuticals

8:40 pm – 8:55 pm Alephoson Biopharmaceuticals

8:55 pm – 9:10 pm Chengdu Hyperway Pharmaceuticals

9:10 pm – 9:25 pm Excellims Corp

9:25 pm – 9:30 pm Group photo and session break

9:30 pm – 9:45 pm Notitia Biotechnologies Company

9:45 pm – 10:00 pm Papyrus Therapeutics Inc.

10:00 pm – 10:15 pm TeamedOn International, Inc.

10:15 pm – 10:30 pm Vivacitas Oncology Inc.

10:30 pm – 10:45 pm Zylö Therapeutics

10:45 pm – 10:50 pm Sponsor remarks

10:50 pm – 11:00 pm Result Announcement & Closing Remarks


Title Sponsor

10 Agenda

Saturday June 26

Morning Sessions

9:00 am – 12:00 pm Plenary Session and Fireside Chats

9:00 am – 9:10 am Opening & SAPA Intro

9:10 am – 9:35 am Keynote: Recent Trends in Biopharma Industry

Umer Raffat, Senior Managing Director, Evercore ISI

9:35 am – 10:00 am Keynote: The Current Investment Landscape for China Biotech

Brad Loncar, CEO, Loncar Investments

10:00 am – 10:25 am Keynote: The Journey from Bench to IPO

Jay Mei, MD, PhD;

Founder, Chairman & CEO of Antengene Corporation

10:25 am – 10:35 am Group Photo, Sponsors’ Presentation Highlights, and Coffee Break

10:35 am – 11:15 am Fireside Chat 1: IPO Capital Markets Overview and Outlook

Lili Zheng, Partner | International Tax | Asia Pacific Cross-Border

Services Leader, Deputy Managing Partner – US Chinese Services

Group, Deloitte Tax LLP

Danny Wang, Managing Director, Audit & Assurance, Audit Leader,

Deloitte US Chinese Services Group, Deloitte & Touche LLP

David Yu, Partner, Audit & Assurance LSHC, Deloitte China

Rebecca Chan, Partner, Audit & Assurance, Deloitte China

11:15 am – 11:55 am Fireside Chat 2: Biotech Innovations in China

Lucy Lu, CFO, Kintor Pharmaceutical Limited

Weimin Tang, PhD, EVP; I-MAB

Brad Loncar, CEO, Loncar Investments

11:55 am – 12:00 pm Closing Remarks

12:00 pm – 1:00 pm Lunch Break

SAPA Events and Sponsors’ Presentation Highlights


Title Sponsor

11 Agenda

Saturday June 26

Afternoon Sessions


Title Sponsor

1:00 pm – 4:30 pm Entrepreneurship Crash Course

1:00 pm – 1:05 pm Opening Remarks

1:05 pm – 1:50 pm An Entrepreneur’s Journey – Start and Build Business in U.S. and

China

Shoufeng Li, PhD, CEO and co-founder of Aucta Pharmaceuticals, Inc.

1:50 pm – 2:30 pm How to Attract Early-Stage Investment

Dennis Ford, Founder & CEO, Life Science Nation (LSN)

Candice He, Director of Pacific Region, Global Investment Strategist, LSN

2:30 pm – 2:40 pm Group Photo, Sponsors’ Presentation Highlights, and Coffee Break

2:40 pm – 3:00 pm Startup BD & Licensing In/Out

Lihua Zheng, JD, PhD, Chief Business Officer & Co-Founder,

AnHeart Therapeutics

3:00 pm – 3:20 pm The Fundamentals of Entity Structuring to Maximize Flexibility for

Partnering, M&A or IPO

Lillian Li, Managing Director – International Tax, Deloitte Tax LLP

Lynn Yang, Managing Director – Transfer Pricing, Deloitte Tax LLP

3:20 pm – 3:40 pm An Introduction to the M&A Process

Michael Weiner, Partner of Fox Rothschild

3:40 pm – 4:25 pm Round Table Clinics Q&A

Panelist:

All afternoon speakers

Jerry Liu, PhD, Partner of Fox Rothschild

Peimin Liu, Senior Manager – International Tax, Deloitte Tax LLP

4:25 pm – 4:30 pm Closing Remarks

4:45 pm – 5:45 pm Breakout and Networking SessionsA: Cross-Border Corporate Structuring: Networking session with Deloitte

B: Key Legal Considerations for Entrepreneurs:

Networking session with Fox Rothchild

C: Employee Benefit Solutions for Small & Large Business:

Networking session with United Healthcare

D: Collaboration and Partnership:

Networking session with AnHeart Therapeutics, Eternity Bioscience,

KLUS Pharma, Legend Biotech, and PwC

E: SAPA Roadshow Entrepreneur Alumni Networking Session

12 Project List

Organization Name Category Disease areaDevelopment

stage

Alephoson

Biopharmaceuticals

Biologics Ophthalmology Pre-clinical

B2Med LLC Small Molecule

Pharmaceuticals

Chronic kidney and

cardiovascular diseases

Phase I

Chengdu Hyperway

Pharmaceuticals

Small Molecule

Pharmaceuticals

Oncology, pain and anti-fungal Pre-clinical

Cipher Surgical Inc Medical Devices/

Diagnostics

Minimally invasive surgery On market

Danuvius Biosciences Medical Devices /

Diagnostics

Infection diseases, chronic and

neurological diseases

Phase I

GATTACO Inc Medical Devices/

Diagnostics

Clinical diagnostic testing,

especially for blood testing.

Commercial

under RUO

InformDS Technologies Bioinformatics/

software

Clinics Digitisation On market

Jinlu Biotechnology Medical Devices/

Diagnostics

Diagnosis assay and testing Ready for

commercialization

Misum Biotech Medical Devices /

Diagnostics

Companion Diagnostics On market

Molecular Theranostics,

LLC

Small Molecule

Pharmaceuticals

Cancer specific MRI and PET

diagnostic imaging drugs

Phase I

Quantum BioTek Inc. Bioinformatics/

Medical Devices/

Diagnostics

Cardiovascular Phase III

TeamedOn International,

Inc.

Gene Therapy Ophthalmology Pre-clinical

Telocyte Genetics &

Genomics

Alzheimer’s disease Pre-clinical

Throne Biotechnologies Cellular Therapy Diabetes, alopecia areata,

Covid-19, Autoimmune disease

Phase II

Yiviva Botanic Medicine Aging-Associated diseases -

including cancer, inflammatory

and chronic diseases

Phase II

13 Organization Name Category Disease areaDevelopment

stage

AB Biosciences Biologics Auto-immune disorders Pre-clinical

Able cerebral, LLC Medical

Device/Diagnosis

All stages of AD, DM and TBI Phase II

Accufusion Therapeutics Biologics Heart failure for the aging

population

Pre-clinical

Acon Pharmaceuticals Nanotechnology/

Drug Delivery/

Formulation

Pulmonary fibrosis; Covid-19 Phase I

Biopegasus Medical

Device/Diagnosis

Alzheimer’s Pre-clinical

Bloom Standard, Inc Medical Devices/

Diagnostics

Congenital heart defects,

pneumonia, and respiratory

diseases

Bench-top testing

Excellims Corp Medical

Devices/Diagnostics

Mass spectrometers

instrumentation

On market

HbO2 Thereapeutics LLC Biologics Hematology Phase III

Notitia Biotechnologies

Company

Microbiome /

Bacteriome

Covid-19, Diabetic kidney

diseases, Cancer

Chemotherapy, Multiple

Sclerosis, Parkinson’s disease

Phase I&II

Papyrus Therapeutics Inc. Biologics Oncology Pre-clinical

Sober Grid, Inc. Software Substance use disorder Phase II

Todos Medical Medical

Device/Diagnosis

Immunology-related Phase II

TRIO Pharmaceuticals,

Inc.

Biologics Oncology Pre-clinical

Vivacitas Oncology Inc. Small Molecule

Pharmaceuticals

Oncology Phase II

Xylyx Bio, Inc. Advanced

biomaterials and

disease models for

drug discovery

ECM-Related Conditions On market

Zylö Therapeutics Drug Delivery Erectile Dysfunction, lupus,

wound-healing

Pre-clinical

14 Project Highlights

from the Past EventsWe have received over 100 projects from different fields in our past roadshow

events. Here are a few examples of the participants and their testimonies.

“I attended the 2019 SAPA Healthcare Investment Forum and Roadshow. SAPARoadshow is a well-established event. It is a good board to meet and get connections.”

Yijun Huang, CEO, Eyekor, Inc., accomplished $20MM Series B funding

“I do enjoy some of your annual meetings which I attended several times. Everybody is doing a great job and contributes their own time and effort. I enjoy the environment, and the organization is quite good.”

Ray Lee, Founder and CMO of Teclison Limited, accomplished $20MM Series A funding

Aimed to harness theintrinsic properties ofhuman cells to convert

into different cell types to address critical unmet needs. Theyare developing specific FOXO1 inhibitors to convert intestinalendocrine cells into glucose-regulated insulin-producing cells inorder to treat insulin-dependent diabetes with an oral agent.

Committed to tumor immune celltherapy of high-tech bio technologyenterprises. They are making full

use of advanced life digitalization technology to stimulate thebody's immune system to fight tumor vitality and develop a newadvanced prevention and treatment plan targeting tumor specificantigen, so that patients can benefit from it.

Focusing on genomicsand cloud technologiesthat will accelerate

research and discoveries, and enable industrial applications.Their product, Atlas OS, is a cloud operating system forgenomics and big data analytics. is a cloud-computingplatform optimized for easy and affordable genomics dataanalytics and management, with the best built-in civilian datasecurity and privacy protection capabilities.

Focused on developingits patented genetransfer technology into

effective treatments for various genetic diseases, infectiousdiseases, and cancers. Their technology, SimVec, is beingemployed for developing gene-based therapeutics for humandiseases including both inherited and infectious diseases.Current research and development is focused on using thistechnology to develop human vaccines against HIV, Hepatitis C,Hepatitis B, and SARS.

A Software-as-a-Service (SaaS)company by providing a first-of-its kind FDA 510(k) cleared

data management system with specific indication for use inOphthalmic Clinical Trials to offer clinical trial stakeholderscomplete data accessibility and accountability, andconsequently enhanced efficiency and accuracy in datacollection and interpretation.

Their goal is to make in-situ lenscleaning the standard of care byscientifically demonstrating its

true value to healthcare systems worldwide. Cipher Surgicalhas developed the OpClear® a single use, regulated surgicaldisposable – the only device that cleans the laparoscope lensof all contaminants in situ during a laparoscopic procedurewithout its removal for cleaning.

15

Arranged alphabetically by the last names.

Bob Ai, PhD, MBA

Managing Director at Solebury Trout &

Board Member at Edoc Acquisition Corp

At Solebury Trout, Bob focuses on Sino-U.S. cross-border banking, strategic consulting

services and investor relations. Prior to joining the firm, Bob was Managing Director, Senior

Biotech Analyst at WallachBeth Capital. Before that, he was the CFO of Aoxing

Pharmaceuticals, a NYSE listed Chinese specialty pharmaceutical company. He has also

served as Principal in the crossover life science private equity firm Merlin Nexus and was

Senior Equity Analyst at asset management firms Bennett Lawrence and Merlin Biomed Group.

Bob received his Ph.D. and MBA degrees from Penn State University and did postdoctoral

training at the University of Pennsylvania. He has published eight articles in peer-reviewed

scientific journals and also won the prestigious Ray Wu scholarship for outstanding Chinese

student to study abroad. Bob holds Series 7, 63, 79, 86, and 87 securities licenses.

Speakers & Panelists

Rebecca Chan

Partner, Audit & Assurance, Deloitte China

Rebecca has over 33 years of experience working with international

accounting firms as well as the Hong Kong Exchanges and Clearing

Limited where she headed the IPO Transactions Department and the

Accounting Affairs Department of their Listing Division. She has been heavily involved in

providing accounting and listing rules advice to clients and working on IPOs and post-listing

transactions. Rebecca also provided regulatory rules suggestions to various overseas stock

exchanges or markets.

She had also acted as a member of the Financial Reporting Advisory Panel of HKEx for the

maximum term of six years. Rebecca is also a past member of the Dual Filing Advisory Group

of the Securities & Futures Commission of Hong Kong responsible for advising on treatment of

cases and policy issues under the dual filing regime for listing in Hong Kong. She is the only

accountant by professional training in town who had acted as the Head of IPO Transactions

Department in HKEx.

16


Dennis Ford

Founder & CEO, Life Science Nation (LSN)

Dennis Ford is an entrepreneur, author, and frontier technologist with

deep expertise in sales, marketing, and business development. He

has wide-ranging experience in hardware and software computing,

middleware, data storage, networking, SaaS, data mining, data

profiling, expert systems, and scaling/funding companies. Through Life Science Nation, Dennis

has created an ecosystem to streamline early-stage fundraising for next-generation drugs,

devices, diagnostics, and digital health products with database subscription services to create

business solutions. Dennis has also pioneered a unique global partnering event model that

matches buyers and sellers based on their specifically stated needs and declared partnering

mandate initiatives garnered from one-on-one interviews and curating buyer/seller databases

in a selected industry. The Redefining Early Stage Investments (RESI) conference series

creates an interactive dialog between buyers and sellers, which uses data profiling and

matching technology to efficiently find that all-important business fit in the marketing and

selling process. He is the author of The Peddler’s Prerogative and The Fund Manager’s

Marketing Manifesto, and The Life Science Executive’s Fundraising Manifesto.

Candice He

Pacific Region, Global Investment Strategist

Life Science Nation (LSN)

Candice He is in charge of the business development on the U.S. west coast and sourcing

Chinese strategic partners at LSN. She is the lead in expanding the business to the Chinese

market and in RESI Shanghai 2019, the first RESI Conference in Asia. She manages

relationships with 3,000+ life science companies on the west coast and 800+ Chinese

investors, as well as participates in the corporate strategy planning. Before joining LSN,

Candice worked for BAC Investments and Bank of New York Mellon. Candice has extensive

networks in both the US and China of life science and technology industry. She got a master’s

degree in finance from Brandeis University in Boston and went to college at Southwestern

University of Finance and Economics in Chengdu, China.

17


Seamus Jiang, MBA

Managing Director, PwC

Seamus is a Deals Managing Director of PwC US based in New York

and Philadelphia with over 20 years of M&A and finance experience in

North America and Asia. He has been assisting strategic and

financial buyers/sellers in evaluating over 200 M&A and investment transactions with an

aggregate deal value of over $200 billion in a variety of industries including many M&A and

capital market projects in the Pharma and Life Sciences sector. Seamus also leads the overall

U.S./China Cross-border Deals practice. In recent years, he has led over 60 U.S./China cross-

border M&A and investment projects spanning across pre-deal strategy, due diligence

execution and post-deal integration and value capture. Seamus earned a B.A. in International

Economics from Fudan University and an M.B.A. from Goizueta Business School of Emory

University. He is a CFA charterholder and holds CPA licenses in both U.S. and China.

Lillian Li

Managing Director – International Tax

Deloitte Tax LLP

Lillian has 20 years’ professional experience in the international tax

area. Lillian assists multi-national clients with tax advantaged

investment structuring, financing, strategies, repatriation techniques,

international tax reporting and global tax minimization. She leads the international tax service

teams of some of Deloitte’s largest clients, including several large asset management firms

and financial institutions. She is a trusted advisor and has in-depth knowledge in analyzing the

issues and opportunities relevant to investment funds, fund organizers, fund investors and their

investment portfolios.

Lillian is also a leader in Deloitte’s Chinese inbound tax services. She has extensive

experience working with Chinese executives and assisting Chinese entities doing business in

the US, especially with entrepreneurs in life sciences & health care industry. Lillian is very

knowledgeable in intangible property planning, IPO positioning, and cross-border M&A.

Lillian is a member of the New York State Bar Association. She graduated from Fudan

University and received her LL.M. degree from New York University School of Law.

18


Shoufeng Li, PhD

\

CEO at Aucta Pharmaceuticals, Inc.

Dr. Shoufeng Li is CEO and co-founder of Aucta Pharmaceuticals,

Inc, a technology-based company creating better products of

proven molecules using 505(b)(2) regulatory pathway and

focusing on the development and commercialization of Branded Specialty Products. Prior

to founding Aucta Pharmaceuticals, Dr. Li is Director, Technical Project Leader at

Novartis Pharmaceuticals Corporation at East Hanover, NJ, where he was managing a

multidisciplinary project teams, he was responsible for late phase project management

and represent CMC function in global project team (GPT). Dr. Li has over 15 years of

multi-national industrial product development experience in both small molecule and

peptide/proteins delivery.

Dr. Li's interest and area of expertise is in 505(b)(2) product development and in vitro - in

vivo correlation, he has been instrumental in overcoming multiple difficult to formulate

bioequivalent products during his tenure at Novartis and was awarded Novartis Leading

Scientist in 2007. He has been invited speakers in international forum for multiple

occasions, and has over 30 peer reviewed research articles, reviews and patents. Dr. Li

holds Ph.D. in Pharmaceutics and M.S. in Statistics from Rutgers University. He has

been actively involved professionally in AAPS, SAPA and BayHelix.

Wansheng Jerry Liu, PhD, JD

Partner and Chair of China Practice, Fox Rothschild LLP

Jerry Liu is a Partner and the Chair of China Practice Group of Fox

Rothschild LLP, a 950-lawyer U.S. law firm. Jerry practices in wide

areas of intellectual property and corporate laws and serves clients

from individuals and start-up companies to Fortune 500 companies in their IP protection,

formation of business entities, contract negotiations, and so on, including investment and

licensing deals valued from multi-million to multi-billion dollars. The China Practice Group he

chairs is comprised of over 30 attorneys nationwide in many areas of laws.

Jerry previously worked as a process chemist at Bristol-Myers Squibb. He obtained Ph.D. in

Organic Chemistry with Professor Sir Derek Barton (Nobel Prize, 1969) from Texas A&M

University, J.D. from Rutgers University School of Law, and B.S./M.S. from Chemistry/Polymer

Science from University of Science and Technology of China (USTC).

Jerry served as the Editor-in-Chief of Rutgers Law Record and SAPA President (2019-2020)

and is serving as Co-Chair of the CNIPA Committee of the New York Intellectual Property Law

Association (NYIPLA) and General Counsel of the USTC Alumni Association of Greater New

York. A frequent speaker on IP laws and FDA regulations, Jerry has over 20 scientific or legal

publications and U.S. patents.

19


Jian Liu, PhD

Chief Scientific Officer and Site Head

Eternity Bioscience Inc.

Dr. Jian Liu is currently the chief scientific officer and site head at

Eternity Bioscience Inc., the Hengrui Medicine Group US R&D center located in Cranbury New

Jersey, in charge of the site operation and drug innovation for oncology, immunology and

neuro degenerative diseases. Dr. Liu obtained a Ph.D. degree in organic and computational

chemistry from UCLA. He joined the medicinal chemistry department in Merck Research

Laboratory at Rahway site in February 2001. Dr. Liu has worked on and managed projects

from target validation, lead identification, and lead optimization to generate multiple preclinical

candidates which went to first in human, phase I, phase II clinic trials. Dr. Liu is an expert in

drug discovery for many therapeutic areas such as osteoporosis, obesity, diabetes,

cardiovascular disease, rheumatoid arthritis, oncology and immunology, pain, and infection

disease. Based on his research work, Dr. Liu has published over 100 peer reviewed papers,

patents, and patent applications. Dr. Liu volunteered as an Executive Council member of Sino-

American Pharmaceutical Professionals Association (SAPA) and was the SAPA 25th president

in 2018. He is currently a board of director member of SAPA. Dr. Liu was honored as the 2019

Outstanding 50 Asian American in Business awardee in New York City.

Peimin Liu

Senior Manager – International Tax, Deloitte Tax LLP

Peimin is a senior international tax manager with over ten years of US

and international tax experience in consulting and compliance

services for clients in cross border transactions between US and

Asia. She is experienced in advising US multinational companies investing in Asia as well as

Chinese companies investing in the U.S. She was a member of the Deloitte Asia Pacific

International Core of Excellence (AP ICE) based in Hong Kong between 2015-2019.

She is also experienced in assisting clients with their cross-border wealth management and tax

planning. She has strong technical expertise in business and individual taxation with

diversified experience in all major tax areas. She serves domestic and international, public

and middle market companies, as well as family office clients.

20


Brad Loncar

CEO, Loncar Investments

Brad Loncar is a biotechnology industry investor and CEO of Loncar

Investments. He is the creator of the Loncar China BioPharma Index.

Brad previously worked in the financial services industry at Franklin

Templeton Investments where he was a member of the Management Training Program, and

was appointed to serve in a Senior Advisor role at the U.S. Department of the Treasury. He

currently writes biotechnology commentary at LoncarBlog, Nasdaq.com, and contributes

opinion pieces to Endpoints News.

Lucy Lu

CFO of Kintor Pharmaceutical Limited

Ms. Lucy Lu was appointed as the Chief Financial Officer of Kintor

Pharmaceutical Limited in December 2019. Ms. Lu is primarily

responsible for financial planning, internal control, investor relations

and public relations of Kintor. Prior to joining Kintor, Ms. Lu has over 13 years of experience in

investment banking business. Ms. Lu joined GF Capital (Hong Kong) Limited in July 2018 with

her last position as the director, head of investment banking business and managing director.

From September 2007 to July 2018, Ms. Lu worked at UBS Securities Hong Kong Limited with

her last position as an executive director in the Asian healthcare group. She has been a

signing Principal for Hong Kong sponsorship IPOs since 2014, when she worked in UBS. From

August 2006 to August 2007, Ms. Lu worked at Credit Suisse (Hong Kong) Limited as an

analyst. Ms. Lu obtained her bachelor’s degree in finance from School of Finance in Renmin

University of China in the PRC in July 2003, and her master’s degree in finance from

Guanghua School of Management in Peking University in the PRC in July 2005.

21


Jay Mei, MD, PhD

Founder, Chairman & CEO of Antengene Corporation

Dr. Mei founded Antengene in 2017, which has since become one of

the leading biotech companies based in China and APAC with strong

drug discovery and clinical development expertise and operational capabilities. Antengene

Corporation became listed in HKEx in November 2020 (SEHK: 6996.HK). Currently,

Antengene is conducting multiple clinical trials in China and other APAC countries/regions,

including two registration studies. The first commercial launch of Antengene’s lead pipeline

product in China and APAC is expected in 2021-2022. Antengene has entered into strategic

partnership with Celgene (now BMS), AstraZeneca and Karyopharm Therapeutics over the

past three years.

Prior to founding Antengene, Dr. Mei served multiple senior roles in clinical development at

Celgene, Novartis and Johnson & Johnson. Dr. Mei was one of the leading members in the

clinical development of multiple blockbuster drugs including REVLIMID®, which is among the

best-selling oncology therapies worldwide. Dr. Mei was also involved in the clinical

development of POMALYST®, another one of the best-selling oncology drugs worldwide, and

IDHIFA®, a first-in-class drug for the treatment of acute myeloid leukemia (AML).

Dr. Mei received his M.D. degree from Xiang-Ya School of Medicine and obtained his Ph.D.

degree in pharmacology and toxicology from the University of Maryland. Dr. Mei also serves as

the Adjunct Professor at Blumberg Institute. Dr. Mei is the author of over 70 publications and

holds multiple patents. Dr. Mei is also a member of many professional associations and

industry organizations, such as ASCO, ASH, SAPA, USCACA, etc.

Umer Raffat

Senior Managing Director Evercore ISI

Umer Raffat is a Senior Managing Director at Evercore ISI and heads

our large cap therapeutics effort spanning Biotech, Pharmaceuticals-

major and Specialty Pharmaceuticals.

Umer has been ranked #1 on twelve separate occasions by Institutional Investor, starting from

his very first year covering the sector. He currently ranks #1 across all three sectors he covers:

biotech, pharma-major and pharma-specialty. Previously, he ranked #1 Rising Star Analyst for

two years in a row.

Umer started his equity research career under Dr. Mark Schoenebaum at Deutsche Bank in

2010, and they moved together to Evercore ISI. Umer has an undergrad in biology from

University of Texas at Arlington and a Masters from Harvard School of Public Health.

In 2020, Umer was inducted into Hall of Fame by Institutional Investor All America Research

Team, a designation for analysts who have earned a No. 1 ranking ten times or more.

22


Weimin Tang, PhD

EVP, I-MAB

Dr. Weimin Tang is currently EVP of I-MAB Biopharma, a clinical

stage biotech company focus on Immunology and Oncology. He

served as Interim CEO/Head of US Business Development, Jiangsu

Hengrui Medicine previously and build Hengrui global business

development team and clinical operation in Princeton, NJ. He was trained as cancer biologist

with PhD in Biochemistry at Rutgers University. He has accumulated more than 20 years of

research and business management experiences with global pharmaceutical companies and

Biotechs such as Synaptic Pharmaceutical, BMS, JNJ, Sanofi, Crown Biosciences, Hengrui

Medicine and I-MAB Biopharma. Through his industry career, he expanded his function from

basic biology to high throughput screening, DMPK and business management. Dr. Tang

received his Bachelor's Degree from Zhejiang University, Master Degree from Chinese

Academy of Sciences.

Daniel Tu, PhD

Director of Business Development, Legend Biotech

Daniel Tu is Director of Business Development at Legend Biotech.

Prior to join Legend in 2017, he served several scientific and

commercial roles at GenScript since 2011, including Director, Head of

Corporate Development of SMAB Bispecific Antibody Platform, Head

of Global Commercial Team of Discovery Biology Business Unit, Scientific Liaison of US

Eastern Region and Senior Scientist of Antibody Department. He received his PhD of

Immunology from joint training of Case Western Reserve University/ West China Hospital of

Sichuan University, and bachelor’s degree of Biotechnology from Life Science College of

Sichuan University.

23


Danny Wang

Managing Director, Audit & Assurance

Audit Leader, Deloitte US Chinese Services Group

Deloitte & Touche LLP

Danny has over 20 years of experience in the financial services industry, where he has led a

number of audits of SEC registrants, broker and dealers in securities and investment advisors.

Danny’s focus is primarily on global audit coordination and execution, SEC reporting and a

variety of technical accounting topics.

Michael Weiner, JD

Partner, Fox Rothschild LLP

Corporate attorney with 40 years’ experience representing early,

middle and later stage companies in a broad range of industries,

including technology and life science. Particular focus on capital

formation, mergers, acquisitions and divestitures.

24


Lynn Yang

Managing Director – Transfer Pricing

Deloitte Tax LLP

With over 20 years of economic consulting and Big 4 experiences,

Lynn specializes in assisting clients with global tax rationalization,

transfer pricing planning, documentation, and audit defense. Lynn has been with Deloitte Tax

LLP for fourteen years.

Lynn has extensive experiences in leading and conducting transfer pricing analyses related to

intercompany services, supply chain alignment, intangible property transfer, cost sharing

arrangements, tangible goods transfer, and intercompany financing. Lynn’s work has spanned

a variety of industries, including pharmaceuticals, chemicals, financial services, commercial

and residential real property, investment advice, and many other sectors.

Lynn is also the transfer pricing leader of Deloitte’s US Chinese Services Group. Lynn has

served numerous Chinese inbound clients to meet their transfer pricing needs. Lynn also

assumes the lead client service or lead tax service role for several large Chinese clients.

Lynn is a board of directors for National Association of Chinese Americans and a member of

The American Economic Association, The Chinese Economist Society, and The International

Economics and Finance Society, respectively.

Lynn received her Ph.D. in economics from University of Colorado - Boulder and her MA and

BA in Economics from People’s (Renmin) University of China.

David Yu

Partner, Audit & Assurance LSHC

Deloitte China

David Yu is deputy audit leader of Deloitte Eastern China region. He is

also the life science healthcare industry leader in audit function. David

has been an Audit Partner of Deloitte China since 2011 and has extensive experience in

auditing companies listed in the U.S. and the China stock markets. He started his career of

Deloitte in Shanghai office and had a two-year working experience in New York office of

Deloitte U.S. firm from 2004 to 2006, then returned to Shanghai. David focuses on U.S.

Generally Accepted Accounting Principles and reporting matters related to U.S. Securities &

Exchange Commission. He has sound experience in leading teams to serve local and

multinational clients.

25


Yiwei Zhang, MD, PhD

CEO of KLUS Pharma

Dr. Yiwei Zhang is the VP of Sichuan Kelun Pharmaceutical

Research Institute, CMC Head of Sichuan Kelun-Biotech, and

CEO of KLUS Pharma. As early as 1984-1990, while at the

Sichuan Academy of Medical Sciences, he engaged in scientific research projects, the

results of which was granted the Third Prize of Science and Technology Progress of

Sichuan Province. After graduating from PhD work at the University of Leeds in England,

he served as a post-doctoral researcher and associate researcher at the Albert Einstein

College of Medicine in New York from 1995 to 2007. He became involved in research that

looked at the biochemistry and molecular biology of AIDS-associated infectious diseases.

In 2007 he started working in biopharmaceuticals, and from 2007 to 2017 he served as a

QC scientist and senior scientist at Imclome Systems Inc. and Eli Lilly and Company. In

January 2018 he joined Kelun-Biotech as QC Director and became Deputy Head of

Quality Unit, and VP of Kelun Pharmaceutical Research Institute. Dr. Yiwei Zhang has

published 22 significant papers in both domestic and international research journals and

his work appears in chapters elsewhere.

Lihua Zheng, JD, PhD

Co-Founder & Chief Business Officer

AnHeart Therapeutics Inc. LLP

Dr. Zheng is both an entrepreneur and a seasoned business advisor

with extensive knowledge of technical, business and legal nature. He

is particularly experienced in transactions for life sciences companies and has guided

transactions valued in total several hundred million dollars in the past few years. Previously he

founded and led a boutique New York law firm specialized in venture financing and intellectual

property transactions. He started his legal career in a wall street international law firm where

he assisted major investment banks with matters relating to public offerings by many

biotechnology issuers on NASDAQ and emerging growth companies with their IP and general

corporate matters.

Dr. Zheng graduated from Fordham University School of Law with Juris Doctor and from

Baylor College of Medicine with PhD in Molecular and Human Genetics. He obtained Master of

Science and Bachelor of Science both from Fudan University. He is licensed to practice law in

the State of New York and at the United States Patent and Trademark Office.

26


Lili Zheng

Partner | International Tax |

Asia Pacific Cross-Border Services Leader

Deputy Managing Partner – US Chinese Services Group

Deloitte Tax LLP

Lili Zheng is a senior US international tax partner at Deloitte with more than 30 years of cross-

border tax planning experience. Leveraging on her extensive experience in Deloitte offices in

San Francisco, Tokyo, Beijing, San Jose and Hong Kong, Ms. Zheng provides practical and

implementable solutions to clients regarding their greenfield investment in the US, M&A, and

cross-border investment entry and exit strategies. She also offers comprehensive support to

US companies aming to enter the Greater China region.

She is a trusted advisor with substantial experience in advising PE/VC funds and their portfolio

companies in IPO positioning & IP planning to access different capital markets globally.

Especially, the years of experience working in Silicon Valley enables her to provide tailored

advices to start-ups at different growing stages. Ms. Zheng has serviced clients from various

industries, including life science & healthcare, financial services, manufacturing, and

technology.

Fluent in Mandarin and Cantonese, Ms. Zheng has a deep understanding of the unique

considerations of companies from Asia Pacific and has been a frequent speaker at different

events and platforms, including SelectUSA and BIO.

Ms. Zheng received her B.S., Accounting and Finance from UC Berkeley and M.S. in Taxation

from Golden Gate University.

27


Daqing (Darren) Cai, PhD

Founder & Managing Partner

Sherpa Healthcare Partners

Cynthis Cai, PhD, MBA, M. Eng.

President, Tharton Consulting

Venture Partner, Viva BioInnovator

Yang Huang, PhD

Director, China Healthcare Research

Credit Suisse

Praveen Kudithipudi, MD, MBA

Director of Business Development

Otsuka Pharma

Roadshow Judges

Bob Ai, PhD, MBA



28


Yaping Shou, MD, PhD

Venture Partner

Lilly Asia Ventures

Mark Tang, PhD, MBA

Partner

Good Health Capital, New York

Chong Xu, PhD

Principal at F-Prime Capital

Mark Young, MBA

Co-Founder and Chief Investment Officer

L Catterton

James Lee, PhD

Principal, Oncology Lead

Cello Health BioConsulting

29


Bob Ai, PhD, MBA



Xiaodong Chen, PhD

SAPA President-elect

Director of CMC Operations, Roivant Sciences

Chenchao Gao, PhD

Manager, Alliance Team and Regulatory Strategy

Daiichi Sankyo

May Huang

Senior Manager

Taiho Oncology

Jiajun Mei, PhD

Associate Director,

Aleon Pharma International

Session Leaders & Moderators

30


Pan Pan, PhD

Business Development Director

KLUS Pharma

Eric Rong

President

Praxgen Pharmaceuticals

John Sun, PhD, MBA

President, SAPA

Global Program Lead, Novartis

Xiaowen Wang, PhD

Senior Scientist

Biologics Upstream Process Research and Development

Merck & Co.

Stephen Xue

Director of Operation

Chipscreen Bioscience (US) Ltd

31 Part of Participating Investors

32 Event Sponsors

Strategic Partners

Title Sponsor

General Sponsors

WWC Professional

Corporation Limited, CPA

33 2020-2021

SAPA Corporate Sponsors

JPMorgan Chase & Co. (NYSE: JPM) is a leading global financial services firm with assets of $3.7 trillion and operations worldwide. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. A component of the Dow Jones Industrial Average, JPMorgan Chase & Co. serves millions of customers in the United States and many of the world's most prominent corporate, institutional and government clients under its J.P. Morgan and Chase brands.

36

37Sino-American

Pharmaceutical

Professionals

Association

h t t p s : / / s a p a w e b . o r g

Science

Education

Collaboration

Career

SAPA Career Talk 8@8 is a virtual webinar serieshosted on the 8th day of every month at 8 pm. Wewill discuss career hot topics and address concernsinterested to SAPA members and friends. Thesesessions are complimentary to all.

2021SAPA

Career Talk 8@8

38

Virtual Session

July 31, 2021

Sino-American

Pharmaceutical

Professionals

Association

2021

CDWCareer Development Workshop

Elevating Leadership

Capabilities


MasterClass

39

Science

Education

Collaboration

Career

October 1 – 2, 2021

DoubleTree by Hilton

Somerset Hotel and

Conference Center

Somerset, NJ 08873

USA

2021

SAPA Annual Conference


Sino-American

Pharmaceutical

Professionals

Association

40 SAPA Introduction

The Sino-American Pharmaceutical Professionals Association (SAPA) was

established in 1993 and is headquartered in the center of the pharmaceutical

corridor in New Jersey, USA. Since its inception, SAPA rapidly became one of the

most active Chinese professional associations in the US with eight chapters and

more than 6,000 members.

SAPA’s members are primarily from large and mid-sized pharmaceutical and

biotech companies in the US, with areas of expertise covering almost every aspect

of pharmaceutical research and development as well as production.

The organization’s large membership base and their superb scientific and technical

abilities has allowed SAPA to be a key source for knowledge exchange on the latest

developments in the pharmaceutical, biotechnology, and generic drug industries,

and promote entrepreneurship, healthcare investment and business cooperation.

As a non-profit organization registered in the US, SAPA receives generous

sponsorship and support from numerous multinational companies in the US and

overseas. SAPA will continue to provide a broad platform for scientific and technical

discussion, talent exchange, collaboration and cooperation, and training for the

colleagues in the pharmaceutical industry from the US and China.

SAPA Sites and Chapters

• SAPA-HQ (Headquarter): New Jersey, USA

• SAPA-NE (New England Chapter): Boston and New England region, USA

• SAPA-GP (Greater Philadelphia Chapter): Philadelphia and other Pennsylvania

areas, USA

• SAPA-MW (Mid-West Chapter): Illinois and Indiana, USA

• SAPA-CT (Connecticut Chapter): Connecticut, USA

• SAPA-DC (DC Chapter): District of Columbia and Maryland, USA

• SAPA-China: Zhengzhou and Beijing, China

Professional Expertise of SAPA Members

• Drug discovery, research and development

• Preclinical and clinical research and development

• Application and registration of new drug and biologics to the US FDA

• Production and manufacture of pharmaceuticals and biological products

• Commercial and marketing of pharmaceutical and biological products

• Generic product development and technology

Sino-American

Pharmaceutical

Professionals

Association

Follow SAPA on:

LinkedIn: SAPA-HQ

WeChat: SAPA-HQ

SAPA Mission:

As a global organization, SAPA’s mission is:

• To promote the advancement of pharmaceutical

science and biotechnology

• To contribute to public health education

• To promote entrepreneurship, healthcare

investment and business cooperation

• To foster the career growth of pharmaceutical

professionals


https://sapaweb.org/event/2021-sapa-investment-roadshow/

Sino-American Pharmaceutical Professionals Association ...

Documents

Transcript of Sino-American Pharmaceutical Professionals Association ...